Centrum 7/6  banner

Par ships authorized generic of Megace ES

Print Friendly, PDF & Email

CHESTNUT RIDGE, N.Y. — Par Pharmaceutical Companies Inc. has released an authorized generic version of Par Specialty Pharmaceutical’s Megace ES oral suspension.

Megace ES oral suspension (megestrol acetate) is a progestin indicated for the treatment of anorexia, cachexia or an unexplained significant weight loss in patients diagnosed with AIDS.

The generic product is available in 150 ml bottles. Par reported that for the first quarter of 2015, its net sales of Megace ES totaled $4.9 million.

Megace is a registered trademark of E.R. Squibb & Sons, licensed to Par Pharmaceutical. In announcing the authorized generic on Wednesday, Par said its launch followed a competitor’s introduction of the first generic version of Megace ES.

On Tuesday, Taipei, Taiwan-based TWi Pharmaceuticals Inc. announced the rollout of a generic version of Par’s Megace ES (megestrol acetate oral suspension, 625 mg/5 ml) after a favorable patent ruling. TWi reported that U.S. sales of Megace ES totaled about $44 million for the year ended in May 2015, according to IMS Health data.


ECRM_06-01-22


Comments are closed.

PP_1170x120_10-25-21